Whole genome miRNA sequencing of CSF from patients diagnosed with PD with mild cognitive impairment (PD–MCI) and treated with the DDR1 inhibitor, nilotinib, demonstrates changes of molecular pathways that regulate angiogenesis and the BBB, neuro-inflammation, and protein clearance via autophagy [30–32]. The gene discussed is DDR1; the disease is Parkinson disease.